Q-omics provides the consensus-scored BBS10 profile across patient tissues and cancer cell-line models. BBS10 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BBS10 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, BBS10 RNA expression shows 21,094 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where BBS10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BBS10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BBS10 survival associations across molecular data types. BBS10 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BBS10 RNA expression–survival associations across cancer types. High BBS10 expression shows unfavorable associations in LIHC, but favorable associations in KIRC, UCS, LUAD, LGG and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BBS10 RNA expression.
This table summarizes BBS10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for BBS10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BBS10 shows lower tumor expression in THCA, UCEC, BRCA and KICH and higher tumor expression in HNSC and LIHC. The THCA box plot shows higher BBS10 RNA expression in normal versus tumor tissue (log2 FC = −0.622, t-test p < 0.001).
This table shows molecular features associated with BBS10 in patient tissues and cancer cell lines. In patient samples, BBS10 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, BBS10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
